In a recent collaboration between Svar Life Science and Genovis, the effects of TransGLYCIT, a transglycosylation modifying enzyme that modifies human IgG1 to carry different glycoforms, on the elicit ADCC (Antibody-dependent Cellular Cytotoxicity) activity was evaluated using the iLite ADCC Cell-based solutions. The work was presented at the recent Antibody Engineering & Therapeutics conference in Amsterdam.
In short, the poster presents data generated by using the transglycosylation workflow TransGLYCIT™ to successfully modify human IgG1 to carry either G0, G1, G2, or G2S2 glycoforms with or without core fucosylation before the ADCC activities were determined using iLite® ADCC Reporter Gene Assay from Svar Life Science.
Get your copy of the poster " Fast and Efficient Evaluation of the Impact of Fc N-glycosylation on Antibody-dependent Cellular Cytotoxicity" by following the link below.
